Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
Aurobindo Pharma
on Wednesday said its wholly- owned arm
Eugia Pharma Specialities
Ltd has received final approval from the USFDA to manufacture and market its generic version of
Dasatinib tablets
indicated in certain types of cancer of bone marrow and blood.
The approval by the US Food & Drug Administration (USFDA) is for manufacturing and marketing of Dasatinib tablets of strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Aurobindo Pharma said in a regulatory filing.
These are bioequivalent and therapeutically equivalent to the reference listed drug
Sprycel Tablets
in the same strengths, of
Bristol-Myers Squibb
Company (BMS), it added.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
If You Eat Ginger Everyday for 1 Month This is What Happens
Tips and Tricks
Undo
The product is expected to be launched in Q1FY26, Aurobindo Pharma said.
The approved product has an estimated market size of USD 1.8 billion for the 12 months ended February 2025, it said citing IQVIA MAT data.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
29 minutes ago
- Time of India
Mumbai NCLT allows 90-day extension of insolvency resolution for Lavasa Corp
Mumbai: The Mumbai bench of National Company Law Tribunal ( NCLT ) has allowed a 90-day extension in the ongoing consolidated corporate insolvency resolution process (CIRP) of Lavasa Corp beginning May 29. The planned city project is undergoing a fresh CIRP after the NCLT, in September 2024, directed that the entire process be restarted, following the successful bidder's failure to implement the approved resolution plan within the specified time frame. The company has admitted liabilities of more than ₹6,642 crore, while the erstwhile successful bidder, Darwin Platform Infrastructure , had proposed to pay ₹1,814 crore. "We are of the view that the present application deserves to be allowed," the division bench of judicial member Ashish Kalia and technical member Sanjiv Dutt observed on June 2. "Since the CIRP is at an advanced stage and resolution plans have already been submitted by PRAs (prospective resolution applicants), which are required to be considered by the CoC (committee of creditors), the extension is being sought in the interest of value maximisation and to ensure that the objectives of the Code ( Insolvency and Bankruptcy Code ) are duly met." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 모공각화증, 저는 집에서 이렇게 해결했어요 (전후사진) 현명한소비자 Undo
Time of India
39 minutes ago
- Time of India
Shongtong-Karcham gets 2026 deadline, HP bets big on hydro
Shimla: Himachal Pradesh chief minister Sukhvinder Singh Sukhu has set a firm Nov 2026 deadline for the completion of the long-delayed Shongtong-Karcham hydroelectric project, saying the 450-MW plant will generate Rs 1,000 crore in annual revenue and strengthen the state's green energy ambitions. Sukhu on Monday inspected the under-construction site in Kinnaur district — visiting both the power house at Karcham and the barrage site at Powari — where he met engineers and workers. He said that even though the project had dragged on for 13 years, the state's current Congress govt had fast-tracked its progress and was committed to commissioning it on schedule. "This project symbolises our focus on tapping river resources to drive economic growth," Sukhu said, adding that the state was moving actively to regain control over stalled or externally-managed hydroelectric initiatives. He claimed that the govt was assessing the total expenditure incurred on other major hydropower projects — including Dhaulasidh, Luhri, and Sunni — with plans to resume and regulate their construction under state-led terms. "Unlike the previous BJP govt, which compromised state interests, we are prioritising Himachal Pradesh's control over its energy assets," Sukhu said. The CM also announced that HP was advancing plans for a geothermal power facility at Tapri in Kinnaur and expanding its capacity in solar and green hydrogen energy. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo Despite being an energy-surplus state, HP still buys electricity from neighbouring states during winter for Rs 5 to 6 a unit. Sukhu said the state was ramping up solar-energy generation to offset this seasonal gap. "It has 626 MW worth of solar-power projects in various stages of development currently through the Himachal Pradesh Power Corporation Limited (HPPCL)," he said. Revenue Minister Jagat Singh Negi and senior district officials accompanied Sukhu during the site visit. MSID:: 121728609 413 |
Time of India
39 minutes ago
- Time of India
North's science & tech cluster launches ‘Syn-Pharma' to boost pharma innovations in region
Chandigarh: The Northern Region Science & Technology Cluster, PI-RAHI, launched its flagship initiative 'Syn-Pharma' at Panjab University Monday to boost pharmaceutical and MedTech innovation in northern India. The platform aims to foster collaborative research, regulatory support, and stronger industry-academia partnerships. The event was inaugurated by Rajeev Singh Raghuvanshi, Drugs Controller General of India, who said, "Innovation must be guided by quality, not just profit. Value must be in the driver's seat. The next six years are crucial for India to show the world it can deliver affordable, high-quality medicines." Highlighting the growing role of the Chandigarh region in drug manufacturing, he called for deeper collaborations. Renu Vig, PU vice-chancellor and chairperson of PI-RAHI, underlined the role of academic institutions in meeting industrial demands. "Academia has always been keen to bridge the gap with industry. I am heartened by the participation of pharmaceutical companies in Syn-Pharma," she said. Vig stressed the need for innovative research that addresses unsolved challenges in healthcare. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Fischamend: Hansaton sucht 250 Testhörer vor 1972 geboren Hansaton Jetzt anmelden Undo Two major initiatives were unveiled under Syn-Pharma. A Call for Proposals will fund up to Rs 10 lakh for joint research projects between institutions and pharma or MedTech firms. A new industry-oriented PhD programme led by NIPER Mohali was also announced to encourage industrial product development. Three startups mentored by PI-RAHI under PSCST's SHE 3.0 initiative were recognised on the occasion. DACH Biotech Pvt Ltd received Rs 3 lakh for work in cancer diagnostics, Nanokem Innovations got Rs 1.5 lakh for nano-based drug delivery, and Herbspark Nutraceuticals received Rs 2 lakh for herbal therapeutics. The initiative is supported by the office of the principal scientific adviser, CDSCO, and RUSA, with key partners including UIPS, PU, NIPER Mohali, and PSCST.
